{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T19:51:17Z","timestamp":1784231477718,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T00:00:00Z","timestamp":1564963200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T00:00:00Z","timestamp":1564963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s15010-019-01347-w","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T03:37:32Z","timestamp":1564976252000},"page":"75-83","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Treatment failure definitions for non-purulent skin and soft tissue infections: a systematic review"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1547-4634","authenticated-orcid":false,"given":"Krishan","family":"Yadav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avik","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn N.","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Sikora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Eagles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,5]]},"reference":[{"key":"1347_CR1","first-page":"ITC11","volume":"150","author":"DL Stevens","year":"2009","unstructured":"Stevens DL, Eron LL. Cellulitis and soft-tissue infections. Ann Intern Med. 2009;150:ITC11.","journal-title":"Ann Intern Med"},{"key":"1347_CR2","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1001\/archinte.168.14.1585","volume":"168","author":"AL Hersh","year":"2008","unstructured":"Hersh AL, Chambers HF, Maselli JH, Gonzales R. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med. 2008;168:1585\u201391.","journal-title":"Arch Intern Med"},{"key":"1347_CR3","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.annemergmed.2007.12.004","volume":"51","author":"DJ Pallin","year":"2008","unstructured":"Pallin DJ, Egan DJ, Pelletier AJ, Espinola JA, Hooper DC, Camargo CA Jr. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med. 2008;51:291\u20138. \nhttps:\/\/doi.org\/10.1016\/j.annemergmed.2007.12.004\n\n.","journal-title":"Ann Emerg Med"},{"key":"1347_CR4","doi-asserted-by":"publisher","first-page":"282","DOI":"10.5811\/westjem.2013.8.18040","volume":"15","author":"DJ Pallin","year":"2014","unstructured":"Pallin DJ, Camargo CA Jr, Schuur JD. Skin infections and antibiotic stewardship: analysis of emergency department prescribing practices, 2007\u20132010. West J Emerg Med. 2014;15:282\u20139. \nhttps:\/\/doi.org\/10.5811\/westjem.2013.8.18040\n\n.","journal-title":"West J Emerg Med"},{"key":"1347_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/MLR.0000000000000261","volume":"53","author":"AK Venkatesh","year":"2015","unstructured":"Venkatesh AK, Dai Y, Ross JS, Schuur JD, Capp R, Krumholz HM. Variation in US hospital emergency department admission rates by clinical condition. Med Care. 2015;53:237\u201344. \nhttps:\/\/doi.org\/10.1097\/MLR.0000000000000261\n\n.","journal-title":"Med Care"},{"key":"1347_CR6","doi-asserted-by":"publisher","first-page":"13492","DOI":"10.1111\/acem.13492","volume":"2018","author":"K Yadav","year":"2018","unstructured":"Yadav K, Suh KN, Eagles D, MacIsaac J, Ritchie D, Bernick J, et al. Predictors of oral antibiotic treatment failure for non-purulent skin and soft tissue infections in the emergency department. Acad Emerg Med. 2018;2018:13492.","journal-title":"Acad Emerg Med"},{"key":"1347_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5811\/westjem.2014.11.24133","volume":"16","author":"DA Talan","year":"2015","unstructured":"Talan DA, Salhi BA, Moran GJ, Mower WR, Hsieh YH, Krishnadasan A, et al. Factors associated with decision to hospitalize emergency department patients with skin and soft tissue infection. West J Emerg Med. 2015;16:89\u201397.","journal-title":"West J Emerg Med"},{"key":"1347_CR8","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jemermed.2014.12.001","volume":"48","author":"CV Pollack Jr","year":"2015","unstructured":"Pollack CV Jr, Amin A, Ford WT Jr, Finley R, Kaye KS, Nguyen HH, et al. Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital. J Emerg Med. 2015;48:508\u201319.","journal-title":"J Emerg Med"},{"key":"1347_CR9","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1093\/cid\/ciu444","volume":"59","author":"DL Stevens","year":"2014","unstructured":"Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59:e10\u201352. \nhttps:\/\/doi.org\/10.1093\/cid\/ciu444\n\n.","journal-title":"Clin Infect Dis"},{"key":"1347_CR10","unstructured":"Lymphoedema Support Network; British Lymphology Society. Consensus document on the management of cellulitis in lymphoedema; December 2016. \nhttps:\/\/www.lymphoedema.org\/images\/pdf\/CellulitisConsensus.pdf\n\n. Accessed 6 Aug 2018."},{"key":"1347_CR11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3947\/ic.2017.49.4.301","volume":"49","author":"YG Kwak","year":"2017","unstructured":"Kwak YG, Choi SH, Kim T, Park SY, Seo SH, Kim MB, et al. Clinical guidelines for the antibiotic treatment for community-acquired skin and soft tissue infection. Infect Chemother. 2017;49:301\u201325. \nhttps:\/\/doi.org\/10.3947\/ic.2017.49.4.301\n\n.","journal-title":"Infect Chemother"},{"key":"1347_CR12","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1016\/j.ajem.2016.05.064","volume":"34","author":"I Obaitan","year":"2016","unstructured":"Obaitan I, Dwyer R, Lipworth AD, Kupper TS, Camargo CA Jr, Hooper DC, et al. Failure of antibiotics in cellulitis trials: a systematic review and meta-analysis. Am J Emerg Med. 2016;34:1645\u201352. \nhttps:\/\/doi.org\/10.1016\/j.ajem.2016.05.064\n\n.","journal-title":"Am J Emerg Med"},{"key":"1347_CR13","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration; Center for Drug Evaluation and Research (CDER). Acute bacterial skin and skin structure infections: developing drugs for treatment. \nhttp:\/\/www.fda.gov\/downloads\/Drugs\/\u2026\/Guidances\/ucm071185.pdf\n\n. Accessed 6 Aug 2018."},{"key":"1347_CR14","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. \nhttps:\/\/doi.org\/10.1371\/journal.pmed\n\n.","journal-title":"PLoS Med"},{"key":"1347_CR15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/jac\/26.suppl_E.13","volume":"26 Suppl E","author":"R Wise","year":"1990","unstructured":"Wise R. The pharmacokinetics of the oral cephalosporins\u2014a review. J Antimicrob Chemother. 1990;26 Suppl E:13\u201320.","journal-title":"J Antimicrob Chemother"},{"key":"1347_CR16","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"1347_CR17","unstructured":"Wells GA, Shea B, O\u2019Connel D, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. \nhttp:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.htm\n\n. Accessed 14 Aug 2018."},{"key":"1347_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1017\/cem.2016.347","volume":"19","author":"K Yadav","year":"2017","unstructured":"Yadav K, Gatien M, Corrales-Medina V, Stiell I. Antimicrobial treatment decision for non-purulent skin and soft tissue infections in the emergency department. CJEM. 2017;19:175\u201380. \nhttps:\/\/doi.org\/10.1017\/cem.2016.347\n\n.","journal-title":"CJEM"},{"key":"1347_CR19","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/bjd.16235","volume":"178","author":"E Smith","year":"2018","unstructured":"Smith E, Patel M, Thomas KS. Which outcomes are reported in cellulitis trials? Results of a review of outcomes included in cellulitis trials and a patient priority setting survey. Br J Dermatol. 2018;178:1028\u201334.","journal-title":"Br J Dermatol"},{"key":"1347_CR20","doi-asserted-by":"publisher","first-page":"004299","DOI":"10.1002\/14651858.cd004299.pub2","volume":"6","author":"SA Kilburn","year":"2010","unstructured":"Kilburn SA, Featherstone P, Higgins B, Brindle R. Interventions for cellulitis and erysipelas. Cochrane Database Syst Rev. 2010;6:004299. \nhttps:\/\/doi.org\/10.1002\/14651858.cd004299.pub2\n\n.","journal-title":"Cochrane Database Syst Rev"},{"key":"1347_CR21","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13063-017-1978-4","volume":"18","author":"PR Williamson","year":"2017","unstructured":"Williamson PR, Altman DG, Bagley H, Barnes KL, Blazeby JM, Brookes ST, et al. The COMET handbook: version 1.0. Trials. 2017;18:280.","journal-title":"Trials"},{"key":"1347_CR22","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1017\/S0033291700009934","volume":"18","author":"HM McCormack","year":"1988","unstructured":"McCormack HM, Horne DJ, Sheather S. Clinical applications of visual analogue scales: a critical review. Psychol Med. 1988;18:1007\u201319.","journal-title":"Psychol Med"},{"key":"1347_CR23","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1097\/01.brs.0000164099.92112.29","volume":"30","author":"JD Childs","year":"2005","unstructured":"Childs JD, Piva SR, Fritz JM. Responsiveness of the numeric pain rating scale in patients with low back pain. Spine. 2005;30:1331\u20134.","journal-title":"Spine"},{"key":"1347_CR24","doi-asserted-by":"publisher","first-page":"e02389\u201316","DOI":"10.1128\/AAC.02389-16","volume":"61","author":"EL Conway","year":"2017","unstructured":"Conway EL, Sellick JA, Kurtzhalts K, Mergenhagen KA. Obesity and heart failure as predictors of failure in outpatient skin and soft tissue infections. Antimicrob Agents Chemother. 2017;61:e02389\u201316.","journal-title":"Antimicrob Agents Chemother"},{"key":"1347_CR25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/jcpt.12402","volume":"41","author":"KR Kaufman","year":"2016","unstructured":"Kaufman KR, Thurber KM, O\u2019Meara JG, Langworthy DR, Kashiwagi DT. Evaluation of cephalexin failure rates in morbidly obese patients with cellulitis. J Clin Pharm Ther. 2016;41:409\u201313.","journal-title":"J Clin Pharm Ther"},{"key":"1347_CR26","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1007\/BF01975848","volume":"10","author":"R Kiani","year":"1991","unstructured":"Kiani R. Double-blind, double-dummy comparison of azithromycin and cephalexin in the treatment of skin and skin structure infections. Eur J Clin Microbiol Infect Dis. 1991;10:880\u20134.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1347_CR27","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.amjmed.2008.01.028","volume":"121","author":"KJ Madaras-Kelly","year":"2008","unstructured":"Madaras-Kelly KJ, Remington RE, Oliphant CM, Sloan KL, Bearden DT. Efficacy of oral beta-lactam versus non-beta-lactam treatment of uncomplicated cellulitis. Am J Med. 2008;121:419\u201325.","journal-title":"Am J Med"},{"key":"1347_CR28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1592\/phco.20.3.199.34780","volume":"20","author":"KJ Madaras-Kelly","year":"2000","unstructured":"Madaras-Kelly KJ, Arbogast R, Jue S. Increased therapeutic failure for cephalexin versus comparator antibiotics in the treatment of uncomplicated outpatient cellulitis. Pharmacotherapy. 2000;20:199\u2013205.","journal-title":"Pharmacotherapy"},{"key":"1347_CR29","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1001\/jama.2017.5653","volume":"317","author":"GJ Moran","year":"2017","unstructured":"Moran GJ, Krishnadasan A, Mower WR, Abrahamian FM, LoVecchio F, Steele MT, et al. Effect of cephalexin plus trimethoprim-sulfamethoxazole vs cephalexin alone on clinical cure of uncomplicated cellulitis: a randomized clinical trial. JAMA. 2017;317:2088\u201396.","journal-title":"JAMA"},{"key":"1347_CR30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1177\/2150131915583659","volume":"6","author":"M Theofiles","year":"2015","unstructured":"Theofiles M, Maxson J, Herges L, Marcelin A, Angstman KB. Cellulitis in obesity: adverse outcomes affected by increases in body mass index. J Prim Care Community Health. 2015;6:233\u20138.","journal-title":"J Prim Care Community Health"},{"key":"1347_CR31","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ajem.2008.03.026","volume":"27","author":"RD Wells","year":"2009","unstructured":"Wells RD, Mason P, Roarty J, Dooley M. Comparison of initial antibiotic choice and treatment of cellulitis in the pre- and post-community-acquired methicillin-resistant Staphylococcus aureus eras. Am J Emerg Med. 2009;27:436\u20139.","journal-title":"Am J Emerg Med"},{"key":"1347_CR32","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1097\/SMJ.0b013e3182387365","volume":"104","author":"MS Bader","year":"2011","unstructured":"Bader MS, Twells L, Hawboldt J. Risk factors of cellulitis treatment failure with once-daily intravenous cefazolin plus oral probenecid. South Med J. 2011;104:789\u201393.","journal-title":"South Med J"},{"key":"1347_CR33","first-page":"139","volume":"12","author":"JC Chan","year":"1995","unstructured":"Chan JC. Ampicillin\/sulbactam versus cefazolin or cefoxitin in the treatment of skin and skin-structure infections of bacterial etiology. Adv Ther. 1995;12:139\u201346.","journal-title":"Adv Ther"},{"key":"1347_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/0002-9343(85)90264-5","volume":"79","author":"LO Gentry","year":"1985","unstructured":"Gentry LO. Treatment of skin, skin structure, bone, and joint infections with ceftazidime. Am J Med. 1985;79:67\u201374.","journal-title":"Am J Med"},{"key":"1347_CR35","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1086\/340056","volume":"34","author":"ML Grayson","year":"2002","unstructured":"Grayson ML, McDonald M, Gibson K, Athan E, Munckhof WJ, Paull P, et al. Once-daily intravenous cefazolin plus oral probenecid is equivalent to once-daily intravenous ceftriaxone plus oral placebo for the treatment of moderate-to-severe cellulitis in adults. Clin Infect Dis. 2002;34:1440\u20138.","journal-title":"Clin Infect Dis"},{"key":"1347_CR36","doi-asserted-by":"publisher","first-page":"ofx094","DOI":"10.1093\/ofid\/ofx094","volume":"4","author":"E Housman","year":"2017","unstructured":"Housman E, Livings SE, Knee A, Schimmel J. Improving management of hospitalized adults with uncomplicated cellulitis or cutaneous abscess. Open Forum Infect Dis. 2017;4:ofx094.","journal-title":"Open Forum Infect Dis"},{"key":"1347_CR37","doi-asserted-by":"publisher","first-page":"519","DOI":"10.5694\/j.1326-5377.1998.tb123398.x","volume":"169","author":"K Leder","year":"1998","unstructured":"Leder K, Turnidge JD, Grayson ML. Home-based treatment of cellulitis with twice-daily cefazolin. Med J Aust. 1998;169:519\u201322.","journal-title":"Med J Aust"},{"key":"1347_CR38","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/0002-9343(85)90145-7","volume":"79","author":"JS Tan","year":"1985","unstructured":"Tan JS, File TM, Salstrom SJ. Timentin versus moxalactam in the treatment of skin and soft tissue infections. Am J Med. 1985;79:130\u20133.","journal-title":"Am J Med"},{"key":"1347_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2019.02.023","author":"K Yadav","year":"2019","unstructured":"Yadav K, Suh KN, Eagles D, Thiruganasambandamoorthy V, Wells GA, Stiell IG. Evaluation of an emergency department to outpatient parenteral antibiotic therapy program for cellulitis. Am J Emerg Med. 2019. \nhttps:\/\/doi.org\/10.1016\/j.ajem.2019.02.023\n\n.","journal-title":"Am J Emerg Med"},{"key":"1347_CR40","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s10096-016-2631-y","volume":"35","author":"J Zhang","year":"2016","unstructured":"Zhang J, Moore E, Bousfield R. OPAT for cellulitis: its benefits and the factors that predispose to longer treatment. Eur J Clin Microbiol Infect Dis. 2016;35:1013\u20135. \nhttps:\/\/doi.org\/10.1007\/s10096-016-2631-y\n\n.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1347_CR41","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/jac\/dku397","volume":"70","author":"CA Aboltins","year":"2015","unstructured":"Aboltins CA, Hutchinson AF, Sinnappu RN, Cresp D, Risteski C, Kathirgamanathan R, et al. Oral versus parenteral antimicrobials for the treatment of cellulitis: a randomized non-inferiority trial. J Antimicrob Chemother. 2015;70:581\u20136. \nhttps:\/\/doi.org\/10.1093\/jac\/dku397\n\n.","journal-title":"J Antimicrob Chemother"},{"key":"1347_CR42","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ajem.2018.04.046","volume":"37","author":"B Cieri","year":"2019","unstructured":"Cieri B, Conway EL, Sellick JA, Mergenhagen KA. Identification of risk factors for failure in patients with skin and soft tissue infections. Am J Emerg Med. 2019;37:48\u201352.","journal-title":"Am J Emerg Med"},{"key":"1347_CR43","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/emermed-2017-207420","volume":"35","author":"D Dalen","year":"2018","unstructured":"Dalen D, Fry A, Campbell SG, Eppler J, Zed PJ. Intravenous cefazolin plus oral probenecid versus oral cephalexin for the treatment of skin and soft tissue infections: a double-blind, non-inferiority, randomised controlled trial. Emerg Med J. 2018;35:492\u20138. \nhttps:\/\/doi.org\/10.1136\/emermed-2017-207420\n\n.","journal-title":"Emerg Med J."},{"key":"1347_CR44","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/archinte.164.15.1669","volume":"164","author":"MJ Hepburn","year":"2004","unstructured":"Hepburn MJ, Dooley DP, Skidmore PJ, Ellis MW, Starnes WF, Hasewinkle WC. Comparison of short-course (5\u00a0days) and standard (10\u00a0days) treatment for uncomplicated cellulitis. Arch Intern Med. 2004;164:1669\u201374.","journal-title":"Arch Intern Med"},{"key":"1347_CR45","first-page":"1072","volume":"171","author":"TC Jenkins","year":"2011","unstructured":"Jenkins TC, Knepper BC, Sabel AL, Sarcone EE, Long JA, Haukoos JS, et al. Decreased antibiotic utilization after implementation of a guideline for inpatient cellulitis and cutaneous abscess. Arch Intern Med. 2011;171:1072\u20139.","journal-title":"Arch Intern Med"},{"key":"1347_CR46","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1086\/656431","volume":"51","author":"TC Jenkins","year":"2010","unstructured":"Jenkins TC, Sabel AL, Sarcone EE, Price CS, Mehler PS, Burman WJ. Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship. Clin Infect Dis. 2010;51:895\u2013903.","journal-title":"Clin Infect Dis"},{"key":"1347_CR47","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1017\/S1481803500014342","volume":"7","author":"H Murray","year":"2005","unstructured":"Murray H, Stiell I, Wells G. Treatment failure in emergency department patients with cellulitis. CJEM. 2005;7:228\u201334.","journal-title":"CJEM"},{"key":"1347_CR48","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/acem.12371","volume":"21","author":"D Peterson","year":"2014","unstructured":"Peterson D, McLeod S, Woolfrey K, McRae A. Predictors of failure of empiric outpatient antibiotic therapy in emergency department patients with uncomplicated cellulitis. Acad Emerg Med. 2014;21:526\u201331.","journal-title":"Acad Emerg Med"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-019-01347-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s15010-019-01347-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-019-01347-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T23:17:47Z","timestamp":1596496667000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s15010-019-01347-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,5]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1347"],"URL":"https:\/\/doi.org\/10.1007\/s15010-019-01347-w","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,5]]},"assertion":[{"value":"7 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}